Posted by Michael Wonder on 24 Apr 2020
PHARMAC won't fund drug Spinraza to help children with spinal muscular atrophy
24 April 2020 - The parents of babies with a rare and debilitating condition will have to wait longer for a drug to prolong their children's lives, after funding for it was not prioritised.
PHARMAC, New Zealand's drug-buying agency, has put a higher priority on other drugs.
The expensive drug shown to prolong the lives of babies with spinal muscular atrophy will not get funding as hoped, and there is no time frame for when it might.
